795 related articles for article (PubMed ID: 30622371)
1. Colorectal cancer vaccines: Tumor-associated antigens
Wagner S; Mullins CS; Linnebacher M
World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy for colorectal cancer].
Tougeron D; Fauquembergue É; Latouche JB
Bull Cancer; 2013 Sep; 100(9):871-85. PubMed ID: 23917703
[TBL] [Abstract][Full Text] [Related]
3. Personalized cancer vaccines: adjuvants are important, too.
Gouttefangeas C; Rammensee HG
Cancer Immunol Immunother; 2018 Dec; 67(12):1911-1918. PubMed ID: 29644387
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for metastatic colorectal cancer: present status and new options.
Ellebaek E; Andersen MH; Svane IM; Straten PT
Scand J Gastroenterol; 2012 Mar; 47(3):315-24. PubMed ID: 22214467
[TBL] [Abstract][Full Text] [Related]
5. Antitumor vaccination using peptide based vaccines.
Eisenbach L; Bar-Haim E; El-Shami K
Immunol Lett; 2000 Sep; 74(1):27-34. PubMed ID: 10996624
[TBL] [Abstract][Full Text] [Related]
6. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?
Parmiani G; Castelli C; Dalerba P; Mortarini R; Rivoltini L; Marincola FM; Anichini A
J Natl Cancer Inst; 2002 Jun; 94(11):805-18. PubMed ID: 12048268
[TBL] [Abstract][Full Text] [Related]
7. Peptide-based vaccines for cancer immunotherapy.
Brinkman JA; Fausch SC; Weber JS; Kast WM
Expert Opin Biol Ther; 2004 Feb; 4(2):181-98. PubMed ID: 14998777
[TBL] [Abstract][Full Text] [Related]
8. Antitumor vaccination: where we stand.
Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in non-renal carcinomas.
Keilholz U
Urologe A; 2004 Sep; 43 Suppl 3():S138-40. PubMed ID: 15148577
[TBL] [Abstract][Full Text] [Related]
10. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines.
Blass E; Ott PA
Nat Rev Clin Oncol; 2021 Apr; 18(4):215-229. PubMed ID: 33473220
[TBL] [Abstract][Full Text] [Related]
11. Tumor-Derived Antigenic Peptides as Potential Cancer Vaccines.
Sotirov S; Dimitrov I
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732150
[TBL] [Abstract][Full Text] [Related]
12. Melanoma vaccines: mixed past, promising future.
Ozao-Choy J; Lee DJ; Faries MB
Surg Clin North Am; 2014 Oct; 94(5):1017-30, viii. PubMed ID: 25245965
[TBL] [Abstract][Full Text] [Related]
13. New strategies to improve the efficacy of colorectal cancer vaccines: from bench to bedside.
Mocellin S
Curr Opin Investig Drugs; 2006 Dec; 7(12):1052-61. PubMed ID: 17209522
[TBL] [Abstract][Full Text] [Related]
14. Neoantigen cancer vaccines: a new star on the horizon.
Li X; You J; Hong L; Liu W; Guo P; Hao X
Cancer Biol Med; 2023 Dec; 21(4):274-311. PubMed ID: 38164734
[TBL] [Abstract][Full Text] [Related]
15. Current developments with peptide-based human tumor vaccines.
Khazaie K; Bonertz A; Beckhove P
Curr Opin Oncol; 2009 Nov; 21(6):524-30. PubMed ID: 19770763
[TBL] [Abstract][Full Text] [Related]
16. Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.
Mørk SK; Skadborg SK; Albieri B; Draghi A; Bol K; Kadivar M; Westergaard MCW; Stoltenborg Granhøj J; Borch A; Petersen NV; Thuesen N; Rasmussen IS; Andreasen LV; Dohn RB; Yde CW; Noergaard N; Lorentzen T; Soerensen AB; Kleine-Kohlbrecher D; Jespersen A; Christensen D; Kringelum J; Donia M; Hadrup SR; Marie Svane I
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782542
[TBL] [Abstract][Full Text] [Related]
17. Preclinical and clinical development of neoantigen vaccines.
Li L; Goedegebuure SP; Gillanders WE
Ann Oncol; 2017 Dec; 28(suppl_12):xii11-xii17. PubMed ID: 29253113
[TBL] [Abstract][Full Text] [Related]
18. Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines.
Mocellin S; Rossi CR; Nitti D; Lise M; Marincola FM
Biochim Biophys Acta; 2003 Dec; 1653(2):61-71. PubMed ID: 14643925
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine.
Shirakawa T; Kitagawa K
Hum Vaccin Immunother; 2018 Jan; 14(1):159-162. PubMed ID: 29048978
[TBL] [Abstract][Full Text] [Related]
20. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
